Amgen news - the latest biotech news from Labiotech.eu

Seven pharma companies form alliance to prepare for future pandemics

Jim Cornall — Thu, 20 Jul 2023 14:00:00 +0000

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

The post Seven pharma companies form alliance to prepare for future pandemics appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

TTP spinout Cellular Origins to focus on cell and gene therapies

Jim Cornall — Tue, 17 Jan 2023 09:37:43 +0000

TTP plc, a technology and product development company, has announced the launch of Cellular Origins. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellular Origins’ proprietary technology addresses the current barriers associated with the manufacture of advanced therapies that are in late-stage development, enabling […]

The post TTP spinout Cellular Origins to focus on cell and gene therapies appeared first on Labiotech.eu.

Positive results from BioAge muscle atrophy trial

Jim Cornall — Tue, 06 Dec 2022 09:24:03 +0000

BioAge Labs, Inc. has announced positive phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ. BGE-105 treatment resulted in statistically significant prevention of muscle atrophy relative to placebo in healthy volunteers aged 65 or older after 10 days of strict bed rest. Muscle atrophy—loss of […]

The post Positive results from BioAge muscle atrophy trial appeared first on Labiotech.eu.

Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx

Liza Laws — Thu, 04 Aug 2022 15:37:30 +0000

A company producing drugs including TAVNEOS to treat autoimmune diseases, plus others dealing with inflammatory disorders and cancer has been bought by biopharmaceutical company, Amgen for $52 per share. ChemoCentryx and Amgen have entered a definitive agreement worth approximately $3.7 billion. Robert Bradway, chairman and chief executive officer at Amgen, said: “The acquisition of ChemoCentryx […]

The post Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx appeared first on Labiotech.eu.

Biocartis and Amgen Shake Hands on Another Cancer Diagnostics Deal

Alex Dale — Tue, 09 Jan 2018 15:28:34 +0000

Biocartis will use its expertise in molecular diagnostics to produce a companion diagnostic test for Amgen’s upcoming cancer drug. Biocartis has signed its second agreement with US pharma giant, Amgen, to develop a companion diagnostic to test the suitability of a drug for a specific patient. Both deals will make use of Biocartis’ Idylla platform, a fully automated […]

The post Biocartis and Amgen Shake Hands on Another Cancer Diagnostics Deal appeared first on Labiotech.eu.

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

Clara Rodríguez Fernández — Wed, 04 Oct 2017 10:55:14 +0000

Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has announced that its Series E round has reached $58M (€50M). Existing investors including dievini Hopp Biotech, Wellington Partners, and AT Impf took part in the fundraising, which […]

The post Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy appeared first on Labiotech.eu.

Scottish Shark Antibodies have caught Amgen’s Eye

Clara Rodríguez Fernández — Tue, 09 May 2017 11:38:16 +0000

Elasmogen and its partner Feldan Therapeutics have signed a research agreement with Amgen to develop shark-inspired antibodies delivered intracellularly. Elasmogen, based in Aberdeen, Scotland, develops soloMER‘s, which are the smallest naturally-occurring antibody binding domains. “They are remarkably stable,” Caroline Barelle told me this morning at BioTrinity in London. “They can survive extreme pH and temperatures […]

The post Scottish Shark Antibodies have caught Amgen’s Eye appeared first on Labiotech.eu.

Novartis Negotiates its Way into the US Migraine Market

Melanie De Almeida — Tue, 25 Apr 2017 14:38:14 +0000

Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring Novartis will get a chunk of the US revenues. After Novartis and Amgen recently completed their second Phase III study for their migraine drug erenumab, the companies have now reworked their commercial partnership. The two pharma giants teamed up back in 2015 to co-develop […]

The post Novartis Negotiates its Way into the US Migraine Market appeared first on Labiotech.eu.

Meet One of the Most Successful German Biotech Leaders Ever

Philip Hemme — Mon, 17 Apr 2017 06:00:42 +0000

Patrick Baeuerle is the German biotech leader I wanted to interview the most (besides Simon Moroney from MorphoSys, who came to our Meetup in Munich last week). Patrick has explored and succeeded in just about every area of life sciences, be it as a highly cited academic researcher, a professor at Freiburg University, head of drug […]

The post Meet One of the Most Successful German Biotech Leaders Ever appeared first on Labiotech.eu.

German Immuno-Oncology Biotech partners up with Biotech Giant Amgen

Clara Rodríguez Fernández — Mon, 09 Jan 2017 13:35:15 +0000

Immatics and Amgen have inked a deal to develop bispecific drug candidates for cancer that could reach over €1B in milestones. Immatics, an immuno-oncology biotech in Tübingen, Germany, has signed an agreement with biotech giant Amgen. Immatics will receive €28.5M ($30M) upfront and up to €475M ($500M) per program and Amgen will be responsible for clinical development, manufacturing and […]

The post German Immuno-Oncology Biotech partners up with Biotech Giant Amgen appeared first on Labiotech.eu.

€36M Fundraising to Sequence the Genome of Ireland

Clara Rodríguez Fernández — Thu, 27 Oct 2016 16:05:18 +0000

Genomics Medicine Ireland (GMI) has raised €36M ($40M) in series A to sequence the genome of the Irish and use the info for the development of new drugs and diagnostics. Genomics Medicine Ireland (GMI) is committed to revolutionizing health care with whole-genome sequencing. The company just raised €36M ($40M) in Series A that will be used to […]

The post €36M Fundraising to Sequence the Genome of Ireland appeared first on Labiotech.eu.

€365M deal for a Danish ‘DNA barcode’ Drug Screening Platform

Clara Rodríguez Fernández — Wed, 05 Oct 2016 14:00:28 +0000

The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish Biotech claims to count with an unprecedented drug discovery platform that can screen billions of compounds way faster and at a lower cost than the big players. Despite its small size, Nuevolution is experienced in collaborating with big Pharma like Merck, Novartis, […]

The post €365M deal for a Danish ‘DNA barcode’ Drug Screening Platform appeared first on Labiotech.eu.

Italian Gene Therapy Biotech aims high by Collaborating with US Giant Amgen

Clara Rodríguez Fernández — Mon, 19 Sep 2016 16:43:33 +0000

Genenta Science and Amgen have teamed up to develop gene therapies for cancer. The Italian biotech from Milan raised €10M in series A funding last year and is already getting ready for clinical trials. Genenta is developing a gene therapy platform for haematopoietic stem cells and wants to bring it to the clinic. Together with the San Raffaele Hospital and Scientific […]

The post Italian Gene Therapy Biotech aims high by Collaborating with US Giant Amgen appeared first on Labiotech.eu.

German Biotech wins FDA Approval for New Liver Cancer Trial

Denise Neves Gameiro — Wed, 24 Feb 2016 16:50:46 +0000

4SC, in Germany, has the FDA’s green light to conduct efficacy trials in the US with a candidate drug against hepatocellular carcinoma. Munich-based 4SC’s lead candidate, resminostat, is a small-molecule being tested in several trials for some of the deadliest cancers. These include liver – which is also known as hepatocellular carcinoma (HCC). Resminostat is an inhibitor of histone […]

The post German Biotech wins FDA Approval for New Liver Cancer Trial appeared first on Labiotech.eu.

Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?

Denise Neves Gameiro — Mon, 22 Feb 2016 15:18:54 +0000

UCB (Belgium) has a monoclonal antibody candidate (romozumab) which has met its primary endpoints for a phase III Osteoporosis trial, FRAME in partnership with Amgen. The drug showed 75% improvement (compared to placebo) and few side effects. UCB in Brussels is developing immunotherapies for a range of chronic diseases, which has now gotten good phase III results for an […]

The post Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis? appeared first on Labiotech.eu.

How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies

Eva Cosson — Tue, 01 Dec 2015 09:15:18 +0000

Blincyto (Blinatumomab) is the first bispecific antibody construct from Amgen’s BiTE proprietary platform to be granted clinical and regulatory validation so far… After the acquisition in 2012 of Micromet, the Munich-based company that first developed Blinatumomab, Amgen kept revealing the potential of this powerful protein… Blincyto was then approved by the FDA as an orphan […]

The post How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies appeared first on Labiotech.eu.

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Dani Bancroft — Fri, 27 Nov 2015 14:43:05 +0000

Sanofi & Regeneron have completed enrollment in the global Phase III for Praulent (alirocumab), which is evaluating its potential cardiovascular benefits for patients with acute coronary syndrome (ACS). The ‘Odyssey Outcomes’ Study has enrolled around 18,000 patients for its trial (phwoar), and if it shows positive results could be a huge success for Sanofi and […]

The post 18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol appeared first on Labiotech.eu.

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Dani Bancroft — Wed, 25 Nov 2015 14:22:34 +0000

Novartis is hitting back in the Biosimilar battleground: now Neulasta, the white blood cell booster for Cancer, is the latest of Amgen’s victims… Neulasta (pegfilgrastim) has been submitted through Novartis’ subsidiary, Sandoz. As a recombinant human granulocyte colony-stimulating factor (G-CSF), pegfilgrastim looks to stimulate the immune system and boost the white cell count. Neulasta is […]

The post Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War! appeared first on Labiotech.eu.

Cinfa Biotech’s Biosimilar is on the Starting Block!

Joachim Eeckhout — Fri, 20 Nov 2015 10:14:03 +0000

Recently launched Cinfa Biotech just treated the first subjects in a clinical trial with its biosimilar of Neulasta®! Cinfa Biotech just announced that the first subjects have been dosed in a clinical trial of B12019, a biosimilar version of Amgen’s Neulasta® (pegfilgrastim) to treat chemotherapy-induced neutropenia. Though chemotherapy is highly effective against cancer, it is […]

The post Cinfa Biotech’s Biosimilar is on the Starting Block! appeared first on Labiotech.eu.

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Julie Lellouche — Mon, 26 Oct 2015 10:00:37 +0000

Amgen is now months away from a European approval with Imlygic (also known as T-VEC) – the first oncolytic immunotherapy for advanced melanoma. The Committee for Medicinal Products for Human Use (CHMP) and the scientific committee of the European Medicines Agency (EMA), have reacted positively. Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, […]

The post The First Ever Oncolytic Immunotherapy is Set to Reach the European Market appeared first on Labiotech.eu.